SEC Form SC 13G/A filed by Alimera Sciences Inc. (Amendment)
$ALIM
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/25/2024 | Buy → Neutral | H.C. Wainwright | |
| 3/25/2024 | $10.00 | Buy | Maxim Group |
| 10/30/2023 | $8.00 | Neutral → Buy | Alliance Global Partners |
| 2/25/2022 | $12.00 → $10.00 | Buy | HC Wainwright & Co. |
| 8/16/2021 | $16.00 → $12.00 | Buy | HC Wainwright & Co. |
Net Revenue up 54% to $27 Million vs. Q2 2023Global End User Demand up 6% vs. Q2 2023Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc. ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. ("ANI"). "We are plea
Conference call scheduled for today at 8:30 a.m. ET Strengthens Rare Disease segment as largest driver of future growth, expected to add approximately $105 million in highly durable branded revenueAdds two commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in key strategic therapeutic area of ophthalmology Anticipated to drive high single digit to low double digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterExpected to generate additional $35 - $38 million in 2025 adjusted non-GAAP EBITDA inclusive of approximately $10 million in identified cost synergies; additional EBITDA contribution expected from a
Net Revenue up 70% to $23 Million vs. Q1 2023Global End User Demand Up 23% vs. Q1 2023Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results. "Our results in this quarter were consistent with our expectations as we continue to integrate YUTIQ into our U.S. business and sup
H.C. Wainwright downgraded Alimera Sciences from Buy to Neutral
Maxim Group initiated coverage of Alimera Sciences with a rating of Buy and set a new price target of $10.00
Alliance Global Partners upgraded Alimera Sciences from Neutral to Buy and set a new price target of $8.00
4 - ALIMERA SCIENCES INC (0001267602) (Issuer)
4 - ALIMERA SCIENCES INC (0001267602) (Issuer)
4 - ALIMERA SCIENCES INC (0001267602) (Issuer)
SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)
SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)
SC 13D/A - ALIMERA SCIENCES INC (0001267602) (Subject)
15-12G - ALIMERA SCIENCES INC (0001267602) (Filer)
EFFECT - ALIMERA SCIENCES INC (0001267602) (Filer)
EFFECT - ALIMERA SCIENCES INC (0001267602) (Filer)
Strengthens Rare Disease segment as largest driver of future growth, adding approximately $105 million in 2024 revenue on a pro forma basisAdds two durable commercial assets ILUVIEN® and YUTIQ® with significant growth potential, expanding ANI's foothold in strategic therapeutic area of ophthalmologyAnticipated to drive high single-digit to low double-digit accretion in adjusted non-GAAP EPS in 2025 and to be substantially accretive thereafterNew capital structure in place, reducing interest expense by approximately $39 million on an annualized basis (1)ANI maintains its 2024 financial guidance for the standalone Company based on continued momentum across Purified Cortrophin® Gel (Cortrophin
PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (NASDAQ:ALIM). The Company expects closing of the acquisition of Alimera Sciences to be consummated and announced today, pending satisfaction or waiver of any remaining customary closing conditions. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical pr
PRINCETON, N.J. and ATLANTA, Sept. 11, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI") and Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company") today jointly announced that they have scheduled the closing of their transaction pursuant to the companies' previously announced Merger Agreement for before the market opens on Monday, September 16, 2024. About ANI Pharmaceuticals, Inc.ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medic
ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera" or the "Company"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately. "As we prepare to enter 2024 with a significantly larger U.S. business, we are excited to have Todd join our team to oversee our U.S. operations and accelerate our growth trajectory," said Rick Eiswirth, Alimera's President and CEO. "Todd brings strong commercial leadership across sales, marketing and market access from b
ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies. "Maggie's experience within growing companies, leading product development, business strategy, supply chain, and commercial teams, along with leading the development of business partnerships, will bring additional operational experience to our board," said Rick Eiswirth, Alimera's Pr
ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of Jason Werner, Chief Operating Officer ("COO"), effective October 2, 2023. In conjunction with this appointment, Dr. Philip Ashman, previously Alimera's Chief Operating Officer and Senior Vice President, Commercial Operations Europe, was appointed President of International Operations. "Jason has been a strong voice and insightful influence on our board since joining earlier this year, and we